[11C]胆碱全身动态PET在原发性甲状旁腺功能亢进中的动力学与剂量学
本研究用全身动态PET研究6例原发性甲状旁腺功能亢进患者[11C]胆碱的生物分布、动力学常数和剂量学。注药后5分钟起即可获得足以术前定位甲状旁腺腺瘤的图像质量。腺瘤的k3、Ki和分布容积显著高于参考甲状腺组织,而K1较低(P<0.05)。
要点
- 注药后5分钟起图像质量可满足甲状旁腺腺瘤术前定位。
- 腺瘤k3、Ki、分布容积高于参考甲状腺组织,K1较低(P<0.05)。
- 肝和肠道摄取较高提示存在肾外排泄途径。
核心结论
- [11C]胆碱注药后5分钟起腺瘤/本底摄取比高,可能支持快速成像方案。
- 全身动态方法揭示肝脏代谢的关键作用、肾脏排泄极少及甲状旁腺腺瘤独特动力学行为。
研究设计与样本
- 对6例临床诊断原发性甲状旁腺功能亢进的患者行50分钟全身动态PET采集,并于注药后100±10分钟行20分钟静态采集。
- 用SUV、组织摄取、器官吸收剂量及多时间图分析和隔室模型动力学建模评估全身分布与药代动力学。
主要发现
- 观察到[11C]胆碱全身快速摄取,注药后5分钟起图像质量足以术前定位甲状旁腺腺瘤。
- 50分钟后平均摄取:肝17.61%±2.82%、肠道5.77%±1.80%、肾2.77%±0.24%、膀胱0.21%±0.16%。
- 胆囊0.019±0.004 mGy/MBq、肝0.037±0.008 mGy/MBq、胰腺0.022±0.005 mGy/MBq、肾0.016±0.005 mGy/MBq、脾0.023±0.009 mGy/MBq为观察到有效剂量最高的器官。
- 甲状旁腺腺瘤的k3、Ki和分布容积显著高于参考甲状腺组织,K1显著较低(P<0.05)。
关键数值与推荐
- 50分钟后肝平均摄取17.61%±2.82%、肠道5.77%±1.80%、肾2.77%±0.24%、膀胱0.21%±0.16%。
- 胆囊、肝、胰腺、肾、脾的吸收剂量分别为0.019±0.004、0.037±0.008、0.022±0.005、0.016±0.005、0.023±0.009 mGy/MBq。
- 腺瘤与参考甲状腺组织比较:k3、Ki、分布容积更高,K1更低(P<0.05)。
临床怎么用
- 可利用注药后5分钟起的高腺瘤/本底摄取比设计快速[11C]胆碱PET成像流程。
- 关注肝、胆囊、胰腺、肾、脾等有效剂量较高器官的剂量学参考。
局限性
- 样本量仅6例原发性甲状旁腺功能亢进患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study investigated the biodistribution profile, kinetic constants, and dosimetry of [11C]choline in patients with primary hyperparathyroidism (pHPT) using total-body dynamic PET (dPET) imaging, to establish a baseline and standard reference for clinical practice. Methods: A 50-min dPET acquisition followed by a 20-min static acquisition at 100 ± 10 min postinjection was performed on 6 patients with a clinical diagnosis of primary hyperparathyroidism. Whole-body [11C]choline distribution and pharmacokinetics were evaluated by SUV, tissue uptake, organ-absorbed doses, and, finally, multitime graphical analysis and kinetic modeling with compartment models. Results: Rapid whole-body uptake of [11C]choline was observed, with adequate image quality for presurgical localization of parathyroid adenomas seen from 5 min postinjection onward. Average uptake values after 50 min for liver (17.61% ± 2.82%) and bowel (5.77% ± 1.80%), compared with kidneys (2.77% ± 0.24%) and urinary bladder (0.21% ± 0.16%), suggested alternative excretion pathways for [11C]choline other than renal clearance. Gallbladder (0.019 ± 0.004 mGy/MBq), liver (0.037 ± 0.008 mGy/MBq), pancreas (0.022 ± 0.005 mGy/MBq), kidneys (0.016 ± 0.005 mGy/MBq), and spleen (0.023 ± 0.009 mGy/MBq) were the organs with the highest observed effective doses. These organs also showcased extreme values among [Formula: see text], [Formula: see text], [Formula: see text], and [Formula: see text], which provide them with the most distinctive kinetic patterns. Parathyroid adenomas exhibited significantly higher k 3, Ki , and distribution volume, and lower K 1, than reference thyroid tissue (P < 0.05). Conclusion: The high adenoma-to-background uptake of [11C]choline observed 5 min postinjection onward may facilitate swift imaging protocols. The total-body dynamic approach further highlighted the pivotal role of liver metabolism, minimal renal excretion, and unique kinetic behaviors of parathyroid adenomas. These data advance our understanding of [11C]choline's uptake and may serve as a reference for future dPET studies.
引用
- Brusa I, Santoro M, Dall'Olio D, et al. Dynamic Total-Body PET Imaging Unfolds [11C]Choline Kinetics and Dosimetry in Primary Hyperparathyroidism. J Nucl Med. 2026. PMID: 41991339. doi:10.2967/jnumed.125.270518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。